Missed Regeneron Pharmaceuticals' Rally? Here Is The Bull Case

If Regeneron Pharmaceuticals sat on your watchlist instead of in your brokerage account, the outcome over the past year may feel like a miss. For Regeneron Pharmaceuticals shareholders, the return over the past year was 25.3%, including dividends. That result came against a backdrop of bullish arguments about a broad pipeline and bearish worries about pricing pressure and reliance on a few key therapies. If you rewind to October 2025, which business bet looked most important to recognise...